Impax Laboratories, a Hayward, California-based specialty pharmaceutical company focused on controlled-release and specialty generics, has appointed J. Kevin Buchi as interim president and chief executive officer (CEO) following the departure of G. Frederick Wilkinson. The company’s board of directors and Mr. Wilkinson have come to a mutual agreement for Mr. Wilkinson to leave his positions as president, CEO, and member of the board as of December 20, 2016. The board’s nominating committee has initiated a search for a permanent president and CEO.

Mr. Buchi, a member of the Impax board of directors, currently serves as president, CEO, and a member of the board of directors of TetraLogic Pharmaceuticals, a Malverne, Pennsylvania-based clinical-stage biopharmaceutical company. Mr. Buchi intends to retire from his position as president and CEO of TetraLogic Pharmaceuticals at the end of the year commensurate with TetraLogic Pharmaceuticals’ previously announced asset sale to Medivir.

Prior to joining TetraLogic Pharmaceuticals in August 2013, Mr. Buchi served as corporate vice president of global branded products at Teva Pharmaceutical Industries from 2011 to May 2012. Before joining Teva, he was CEO of Cephalon, which was acquired by Teva in October 2011. Mr. Buchi joined Cephalon in 1991 and held various leadership positions, including chief financial officer and chief operating officer, before becoming Cephalon’s CEO in December 2010.

In addition to serving as a director of Impax and TetraLogic Pharmaceuticals, Mr. Buchi has since 2013 served as a director of Benitec Biopharma, biotechnology company headquartered in Australia. He has extensive experience as a director having previously served on the board of a number of pharmaceutical companies including EPIRUS Biopharmaceuticals, Alexza Pharmaceuticals, and Forward Pharma A/S.

Source: Impax Laboratories